On Tuesday April 8th the House Subcommittee on Health (of the Ways and Means Committee) held a hearing on lowering costs for patients and the health of the biosimilar market. The testimony of several experts in the biologics and biosimilar areas supported the need to recalibrate PBMs’ relationship to the biosimilar market as well as … Continue reading Biosimilar Hearings Day in Congress